Imagine a world where doctors are able to target and remove pathogens, such as harmful cells, bacteria, toxins, and inflammatory cytokines, directly from a patient’s bloodstream. That is MediSieve’s vision for the future of healthcare, which can be achieved through the process of Magnetic Blood Filtration.
MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.
MediSieve plans to use a combination of different magnetic beads to target the various pathogens and cytokines that lead to the symptoms of Sepsis.
The device rapidly reduces the parasitaemia of severe Malaria patients who have been hospitalised and prescribed IV drug treatment.
The MediSieve System purifies blood by targeting harmful substances with magnetic beads
Virtual, hosted by Pharmaceutical Business Conference Group
BioInvestor Forum (New York) - 10th - 11th February 2020
Magnetic Blood Filtration Platform shown to be safe and well tolerated, with no serious adv...
Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s Magnetic Haemofilt...